Tuesday, July 31, 2007 - 10:30 AM
S83
Small natural molecules targeting angiogenesis
Ho Jeong Kwon and Hye Jin Jung. Department of Biotechnology, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, Seoul, 120-749, South Korea
Natural products
My lab has applied chemical genomics to identify new targets relevant for cellular function and to develop specific small molecules that can control angiogenesis. Several structurally distinct small natural molecules such as curcumin, terpestacin, and homoisoflavanone were isolated from microorganisms and plants as angiogenesis inhibitors based on their phenotype suppression activity toward endothelial cells. Using affinity selected phage display biopanning and reverse chemical genomics approach, specific functional targets of the small natural molecules have been identified. Biophysical, biochemical and cellular analysis validate the specific interaction between the small molecules and targets. Eventually, all these newly identified targets (i.e., genes or proteins) and small natural molecules can be integrated to develop more potent and clinically druggable agents using high throughput or contents technologies as well as structure based virtual screening of chemical libraries. In this presentation, our recent results and efforts using small natural molecules as probes for biology and drug development will be presented.
My lab has applied chemical genomics to identify new targets relevant for cellular function and to develop specific small molecules that can control angiogenesis. Several structurally distinct small natural molecules such as curcumin, terpestacin, and homoisoflavanone were isolated from microorganisms and plants as angiogenesis inhibitors based on their phenotype suppression activity toward endothelial cells. Using affinity selected phage display biopanning and reverse chemical genomics approach, specific functional targets of the small natural molecules have been identified. Biophysical, biochemical and cellular analysis validate the specific interaction between the small molecules and targets. Eventually, all these newly identified targets (i.e., genes or proteins) and small natural molecules can be integrated to develop more potent and clinically druggable agents using high throughput or contents technologies as well as structure based virtual screening of chemical libraries. In this presentation, our recent results and efforts using small natural molecules as probes for biology and drug development will be presented.